Day 1Monday, 3 November 2025

Location: Room 1

In an era of rapid scientific breakthroughs, evolving regulatory landscapes, and shifting economic pressures, the biopharma industry’s dealmaking and M&A environment is pulsating with opportunity and complexity. This session unravels the forces shaping the future of biopharma partnerships. Dive into real-world case studies—spanning transformative M&As, innovative licensing agreements, and cross-border collaborations that highlight strategies for navigating valuation challenges, harnessing AI-driven innovation, and addressing unmet medical needs. The panelist, comprising of pharmaceutical executives, legal advisors, and investors, will debunk myths surrounding strategic collaborations, such as overreliance on traditional deal structures or underestimating cultural alignment in partnerships. From leveraging venture debt to bridge funding gaps to optimizing alliance management for long-term success, this session equips pharmaceutical executives, investors, and innovators with actionable insights to thrive in what is left of 2025 and beyond. Join us to explore how to orchestrate synergies, mitigate risks, and drive transformative healthcare solutions in a dynamic global ecosystem.